RxDoctor Payments DataLook up a doctor →

Drew Glover, MD

Sports Medicine · Warrensburg, MONPI 1992094908

Payments from drug & device makers

$7,747in general payments, 2019–2025

Across 509 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$883
  • Lilly USA, LLC$715
  • AstraZeneca$625
  • Amgen$580
  • Merck$541
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$7,732100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,747 in reported general payments places this provider in the 70th percentile of 127 sports medicine providers in Missouri.

See all sports medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$5,731
Medicare patients
36
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$48,373
FarxigaDapagliflozin Propanediol47$36,322
OzempicSemaglutide30$29,872
JardianceEmpagliflozin30$22,397
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$20,705
RybelsusSemaglutide11$18,637
Repatha SureclickEvolocumab23$18,566
TrulicityDulaglutide15$14,746
Tresiba Flextouch U-200Insulin Degludec24$12,722
Repatha SyringeEvolocumab12$12,543
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,100
Tresiba Flextouch U-100Insulin Degludec19$11,106
LinzessLinaclotide12$6,305
DayvigoLemborexant14$4,852
Insulin Lispro Kwikpen U-100Insulin Lispro20$4,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$625$57,02774 claims
Novo NordiskOzempic, Rybelsus$883$48,50941 claims
PfizerEliquis$471$48,37359 claims
Boehringer IngelheimJardiance$187$22,39730 claims
GSKTrelegy Ellipta, Arexvy$121$15,42430 claims
Lilly USA, LLCTrulicity$715$14,74615 claims
AbbVieLinzess$1,320$6,30512 claims
Eisai Inc.Dayvigo$105$4,85214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 127 sports medicine providers in Missouri.

Other sports medicine in Warrensburg

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →